IDEXX(US:IDXX) Financial Modeling Prep·2026-02-02 20:00Core Viewpoint - IDEXX Laboratories, Inc. is a leading player in the animal diagnostics industry, showcasing strong financial performance and exceeding market expectations in its latest earnings report for Q4 2025 [1] Financial Performance - IDEXX reported an earnings per share (EPS) of $3.08 for Q4 2025, surpassing the Zacks Consensus Estimate of $2.93, and showing a significant increase from $2.62 EPS in the same quarter the previous year, with an earnings surprise of +5.17% [2] - The company achieved approximately $1.09 billion in revenue for the quarter ending December 2025, exceeding the Zacks Consensus Estimate by 1.86%, and representing a notable increase from $954.29 million in revenue reported a year ago [2] Revenue Growth - Revenue growth was primarily driven by the Companion Animal Group (CAG), which reported a 15% increase in revenue and a 13% organic growth [3] Financial Metrics - IDEXX has a price-to-earnings (P/E) ratio of approximately 50.82, indicating that investors are willing to pay over 50 times the company's earnings for its shares [3] - The price-to-sales ratio stands at about 12.49, suggesting that the market values the company at over 12 times its annual sales [3] - The company's debt-to-equity ratio is approximately 0.71, indicating a moderate level of debt compared to its equity [3] - IDEXX demonstrates a reasonable level of short-term financial health with a current ratio of about 1.12, having slightly higher current assets compared to current liabilities [3]